EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Ubiquitin-Mediated Effects on Oncogenesis during EBV and KSHV Infection

Rachel Mund iD, Christopher B Whitehurst iD

Viruses · 2024

DOI: 10.3390/v16101523 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Rachel Mund und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA. Hauptthemen laut MEDLINE: Herpesvirus 8, Human, Herpesvirus 4, Human, Carcinogenesis, Ubiquitin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, New York Medical College, NIH NIAID.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Herpesviridae include the Epstein–Barr Virus (EBV) and the Kaposi Sarcoma-associated Herpesvirus (KSHV), both of which are oncogenic gamma-herpesviruses. These viruses manipulate host cellular mechanisms, including through ubiquitin-mediated pathways, to promote viral replication and oncogenesis. Ubiquitin, a regulatory protein which tags substrates for degradation or alters their function, is manipulated by both EBV and KSHV to facilitate viral persistence and cancer development. EBV infects approximately 90% of the global population and is implicated in malignancies including Burkitt lymphoma (BL), Hodgkin lymphoma (HL), post-transplant lymphoproliferative disorder (PTLD), and nasopharyngeal carcinoma. EBV latency proteins, notably LMP1 and EBNA3C, use ubiquitin-mediated mechanisms to inhibit apoptosis, promote cell proliferation, and interfere with DNA repair, contributing to tumorigenesis. EBV’s lytic proteins, including BZLF1 and BPLF1, further disrupt cellular processes to favor oncogenesis. Similarly, KSHV, a causative agent of Kaposi’s Sarcoma and lymphoproliferative disorders, has a latency-associated nuclear antigen (LANA) and other latency proteins that manipulate ubiquitin pathways to degrade tumor suppressors, stabilize oncogenic proteins, and evade immune responses. KSHV’s lytic cycle proteins, such as RTA and Orf64, also use ubiquitin-mediated strategies to impair immune functions and promote oncogenesis. This review explores the ubiquitin-mediated interactions of EBV and KSHV proteins, elucidating their roles in viral oncogenesis. Understanding these mechanisms offers insights into the similarities between the viruses, as well as provoking thought about potential therapeutic targets for herpesvirus-associated cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Herpesvirus 8, HumanHerpesvirus 4, HumanCarcinogenesisUbiquitinEpstein-Barr Virus InfectionsVirus LatencyHumansVirus ReplicationViral ProteinsHerpesviridae InfectionsHost-Pathogen InteractionsAnimalsSarcoma, Kaposi

Stichwörter der Autor:innen

EBVEpstein–Barr VirusKSHVKaposi Sarcoma-associated Herpesvirusgammaherpesvirusoncogenesispost-translational modificationproteasomal degradationtumor virusubiquitin

Substanzen

UbiquitinViral Proteins

Autor:innen und Institutionen

  • Department of Pathology, Microbiology and Immunology, New York Medical College, Valhalla, NY 10595, USA.

ORCID-Profile: Rachel Mund, Christopher B Whitehurst

Förderung

  • NIAID NIH HHS
  • New York Medical College
  • NIH NIAID
  • NIAID
  • NYMC

Zitieren

APA

Mund, R., & Whitehurst, C. B. (2024). Ubiquitin-Mediated Effects on Oncogenesis during EBV and KSHV Infection. Viruses. https://doi.org/10.3390/v16101523

Vancouver

Mund R, Whitehurst CB. Ubiquitin-Mediated Effects on Oncogenesis during EBV and KSHV Infection. Viruses. 2024. doi:10.3390/v16101523

BibTeX
@article{Mund2024,
  author = {Mund, Rachel and Whitehurst, Christopher B},
  title = {Ubiquitin-Mediated Effects on Oncogenesis during EBV and KSHV Infection},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16101523}
}
Kostenlos starten →